Bivamelagon (Rhythm) license amended: total $855m (~₩1.15tn) from $305m; +$350m upfront/4y; royalty → 1%
Tue 3 Nov 10:50 KST: LG Chem (051910, ~₩16.94tn) amends the Jan 2024 Rhythm Pharmaceuticals license for oral MC4R rare-obesity candidate bivamelagon — total deal face rises from $305m (~₩400bn) to $855m (~₩1.15tn at ₩1,341/USD). MIXED because non-refundable economics expand (extra $350m upfront over 4 years ≈ ₩469bn / ~2.8% of mcap; milestones $205m→$405m) while the sales royalty is cut from mid-single-digit % to a flat 1% of the MC4R portfolio, and cash still hinges on clinical/approval success. Band only 1–3%: liquid mega-cap (~₩17tn) + multi-year/contingent cash — refuse mid/8%+ even though headline ≈6.8% of mcap (sales%≠band; incremental cash is the right size). Session high already +3.1% then live flat ~0% → small band largely printed on the spike; leftover don’t-chase, p≈18%.
Why direction: MIXED: +$350m non-refundable upfront/4y and higher milestones expand cash, but royalty cut mid-single → 1% and clinical conditionality offset a clean UP. · Why magnitude: 1–3%: ~₩17tn liquid mega; incremental cash ~2.8–4.4% mcap but multi-year/contingent — refuse mid/8%+ despite $855m headline. · Why probability: p≈18%: high already +3.1% cleared the small band then live flat — don’t-chase residual only.
DART 20261103800145 · desk markets-desk